The real-world applicability of GLP-1 RAs in reducing alcohol consumption is particularly relevant for individuals with comorbid obesity or type 2 diabetes mellitus (T2DM)—populations that often have higher rates of alcohol use and face compounded health risks. The gene discussed is GLP1R; the disease is obesity due to melanocortin 4 receptor deficiency.